G. Mondragon-Ramirezj, R. Reyes-Acevedok,

*Drs. Vincenti and Larsen contributed equally to the work described. The clinical profile of belatacept in kidney transplant recipients was evaluated to determine if earlier re-sults in the BENEFIT study were sustained at 3 years. BENEFIT is a randomized 3 year, phase III study in adults receiving a kidney transplant from a living or standard criteria deceased donor. Patients were ran-domized to a more (MI) or less intensive (LI) regi-men of belatacept, or cyclosporine. 471/666 patients completed ≥3 years of therapy. A total of 92 % (MI), 92 % (LI), and 89 % (cyclosporine) of patients survived with a functioning graft. The mean calculated GFR (cGFR) was ∼21 mL/min/1.73 m2 higher in the be